Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
Stopped early · Phase 2
Conditions studied: Breast Cancer, Triple Negative Breast Cancer
In brief
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).
Key facts
- Study ID
- NCT04849364
- Run by
- Bryan Schneider, MD
- People needed
- 52
- Starts
- 2021-08-24
- Expected to finish
- 2024-12-02
- Last updated by the study team
- 2025-05-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama at Birmingham — Birmingham, Alabama, United States
- Georgetown University — Washington D.C., District of Columbia, United States
- Memorial Healthcare System — Hollywood, Florida, United States
- Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida, United States
- University of Chicago Medical Center — Chicago, Illinois, United States
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana, United States
- Summit Health — Berkeley Heights, New Jersey, United States
- Novant Health Cancer Institute — Winston-Salem, North Carolina, United States
- Mays Cancer Center at UT Health San Antonio — San Antonio, Texas, United States
- University of Wisconsin — Madison, Wisconsin, United States
- Froedtert and The Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- Advocate Aurora Research Institute (Illinois) — Wauwatosa, Wisconsin, United States
- Aurora Health Care — Wauwatosa, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.